Celgene is an integrated global biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation.

Employee Rating

4More
StateClosed
TypeSubsidiary
Parent CompanyBristol-Myers Squibb
HQSummit, NJ, US
Founded1986
Websitecelgene.com
Cybersecurity ratingCMore
Celgene was founded in 1986 and is headquartered in Summit, NJ, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Celgene

Mark J. Alles

Mark J. Alles

Chairman and Chief Executive Officer
Zeba M. Khan

Zeba M. Khan

Vice President Corporate Responsibility
John Vogler

John Vogler

Director Environment, Health & Safety
Reimund Tauer

Reimund Tauer

Director, CAR T Commercial Operations
Kimberly Lounds Foster

Kimberly Lounds Foster

Corporate Vice President Global Supply
Jens Hasskarl

Jens Hasskarl

Executive Medical Director, Head Europe Cellular Therapy Clinical Center of Excellence
Show more

Celgene Office Locations

Celgene has offices in Summit, Singapore and Boudry
Summit, NJ, US (HQ)
86 Morris Ave
Singapore, SG
200 Newton Road #04-01, Newton 200
Boudry, CH
Route de Perreux 1
Show all (3)

Celgene Financials and Metrics

Summary Metrics

Founding Date

1986
Celgene is a subsidiary of Bristol-Myers Squibb

Celgene Revenue

Embed Graph
View revenue for all periods
Celgene's revenue was reported to be $15.28 b in FY, 2018 which is a 17.5% increase from the previous period.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

11.2b13.0b15.3b

Revenue growth, %

21%16%18%

Cost of goods sold

438.0m461.0m587.0m

Gross profit

10.8b12.5b14.7b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.0b3.3b3.3b3.5b3.8b3.9b4.0b4.4b4.5b

Cost of goods sold

113.0m111.0m118.0m135.0m126.0m157.0m140.0m151.0m167.0m

Gross profit

2.8b3.2b3.2b3.4b3.7b3.7b3.9b4.2b4.4b

Gross profit Margin, %

96%97%96%96%97%96%97%97%96%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

6.2b7.0b4.2b

Accounts Receivable

1.6b1.9b2.1b

Inventories

497.9m541.0m458.0m

Current Assets

10.9b14.9b9.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

5.3b6.7b5.5b2.8b1.5b2.5b5.4b7.2b9.6b

Accounts Receivable

1.6b1.7b1.8b2.0b2.1b2.1b2.3b2.5b2.4b

Inventories

509.0m533.0m537.0m536.0m555.0m510.0m442.0m464.0m451.0m

Current Assets

11.6b13.1b14.8b7.9b6.9b7.8b11.0b12.7b14.5b
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

2.0b2.9b4.0b

Depreciation and Amortization

504.7m471.0m635.0m

Inventories

(55.3m)(42.0m)82.0m

Accounts Payable

618.9m273.0m290.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

941.0m2.0b3.0b846.0m1.9b3.0b1.5b3.1b4.8b

Depreciation and Amortization

121.0m240.0m355.0m126.0m296.0m465.0m157.0m315.0m486.0m

Inventories

(10.0m)(32.0m)(37.0m)6.0m(14.0m)31.0m16.0m(5.0m)7.0m

Accounts Payable

(365.0m)219.0m28.0m(219.0m)(144.0m)(66.0m)(28.0m)71.0m84.0m
USDFY, 2016

Revenue/Employee

1.6m

Debt/Equity

21 x

Debt/Assets

4.9 x

Financial Leverage

4.3 x
Show all financial metrics

Celgene Operating Metrics

FY, 2016FY, 2017FY, 2018

Active Clinical Studies

52

Phase I Trials Products (Multiple Myeloma)

644

Phase I/II Trials Products (Multiple Myeloma)

1

Phase II Trials Products (Multiple Myeloma)

11
Show all operating metrics

Celgene Acquisitions / Subsidiaries

Company NameDateDeal Size
Juno TherapeuticsJanuary 22, 2018$9 b
Impact BiomedicinesJanuary 07, 2018
DeliniaJanuary 26, 2017$300 m
AnokionJanuary 10, 2017$45 m
Acetylon PharmaceuticalsDecember 02, 2016
EngMabOctober 17, 2016$600 m
ReceptosJuly 14, 2015$7.3 b
Quanticel PharmaceuticalsApril 27, 2015$485 m
Avila TherapeuticsJanuary 26, 2012$350 m
Abraxis BioScienceJune 30, 2010

Celgene Revenue Breakdown

Embed Graph

Celgene revenue breakdown by business segment: 89.4% from Hematology / Oncology, 10.5% from Inflammation & Immunology and 0.1% from Other

Celgene revenue breakdown by geographic segment: 34.4% from International and 65.6% from U.S.

Human Capital Metrics

Celgene's employees are reported to be approximately 52% female and 48% male.
Embed Graph
Show all human capital metrics

Celgene Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Celgene Online and Social Media Presence

Embed Graph

Celgene Company Culture

  • Overall Culture

    A-

    76/100

  • CEO Rating

    D-

    57/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Celgene News and Updates

Global CAR T-cell Therapy Market Trajectory & Analytics Report 2020-2027 Featuring bluebird bio, CARsgen Therapeutics, Celgene Corp, Gilead Sciences, & Novartis

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global CAR T-cell Therapy Market to Reach $8.3 Billion by 2027Amid the COVID-19 crisis, the global market for CAR T-cell Thera…

Cipla spurts on settling litigation with Celgene Corp for cancer drug Revlimid

Cipla rose 3.70% to Rs 783.85 after the drug major announced the settlement of its litigation with Celgene Corporation relating to patents for Revlimid (lenalidomide).

Brand change for Celgene

Celgene becomes Bristol Myers Squibb. The American biotechnology company was swallowed up at the end of 2019 by this other giant of the American pharma. For a week now, and as agreed upon during the acquisition, the name Celgene gives way to that of Bristol Myers Squibb

Celgene, Teva schemed to keep drug prices high, boost profits, US House panel finds

A report released Sept. 30 by the House Oversight and Reform Committee shows that Celgene and Teva intentionally increased the prices of their drugs Revlimid and Copaxone to boost profits

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday by Nick Paul Taylor | Sep 22, 2020 9:15am

Bristol Myers Squibb has received a March 27 PDUFA date for its anti-BCMA CAR T-cell therapy. The priority review action date sets Bristol Myers up to win approval for the bluebird bio-partnered drug in time to satisfy the terms of its acquisition of Celgene

Dr. Reddy’s Settles Patent Suit With Celgene Over Cancer Drug

The firm settled a litigation with Celgene for patents for generic version of a prescription medicine used to treat blood cancer.
Show more

Celgene Frequently Asked Questions

  • When was Celgene founded?

    Celgene was founded in 1986.

  • Who are Celgene key executives?

    Celgene's key executives are Mark J. Alles, Zeba M. Khan and John Vogler.

  • How many employees does Celgene have?

    Celgene has 8,852 employees.

  • What is Celgene revenue?

    Latest Celgene annual revenue is $15.3 b.

  • What is Celgene revenue per employee?

    Latest Celgene revenue per employee is $1.7 m.

  • Who are Celgene competitors?

    Competitors of Celgene include BioNTech, Sanofi and Idorsia.

  • Where is Celgene headquarters?

    Celgene headquarters is located at 86 Morris Ave, Summit.

  • Where are Celgene offices?

    Celgene has offices in Summit, Singapore and Boudry.

  • How many offices does Celgene have?

    Celgene has 3 offices.